Mode
Text Size
Log in / Sign up
N/A Completed N=227

Evaluate The Clinical Effectiveness, Safety And Tolerability Of Sildenafil Used In Doses ≥20mg TID For The Treatment Of Pulmonary Arterial Hypertension

Source: ClinicalTrials.gov NCT01365585 ↗
Enrolled (actual)
227
Serious AEs
0.0%
Results posted
Oct 2012
Primary outcomePrimary: Change From Baseline in 6-Minute Walk Distance (6MWD) at Year 1 — 29.4 meter

Summary

The objective of this observational study is to gain clinical insight on the actual use of sildenafil citrate (Revatio™) for the treatment of pulmonary arterial hypertension (PAH). The primary objective is to assess effectiveness and safety of sildenafil at doses ≥20mg three times daily for the treatment of PAH.

Outcome Measures

OutcomeResultp-value
PRIMARY
Change From Baseline in 6-Minute Walk Distance (6MWD) at Year 1
29.4 —
PRIMARY
Change From Baseline in 6-Minute Walk Distance (6MWD) at Year 2
20.8 —
PRIMARY
Change From Baseline in 6-Minute Walk Distance (6MWD) at Year 3
8.7 —
PRIMARY
Change From Baseline in 6-Minute Walk Distance (6MWD) at Year 4
-50.2 —
SECONDARY
Change From Baseline in New York Heart Association, World Health Organization (NYHA/WHO) Functional Class in Participants With Pulmonary Arterial Hypertension (PAH) at Year 1, 2, 3 and 4
3; 36; 140; 12; 5; 1 —
SECONDARY
Change From Baseline in Right Atrial Pressure (RAP) at Year 1, 2, 3 and 4
— —
SECONDARY
Change From Baseline in Mean Pulmonary Arterial Pressure (mPAP) at Rest at Year 1, 2, 3 and 4
— —
SECONDARY
Change From Baseline in Pulmonary Vascular Resistance (PVR) at Year 1, 2, 3 and 4
— —
SECONDARY
Change From Baseline in Cardiac Index (CI) at Year 1, 2, 3 and 4
— —
SECONDARY
Change From Baseline in Pulmonary Capillary Wedge Pressure (PCWP) at Year 1, 2, 3 and 4
— —
SECONDARY
Change From Baseline in Borg Dyspnea Index at Year 1, 2, 3 and 4
-0.4; 0.0; 0.3; 0.4 —

Eligibility Criteria

Inclusion Criteria

  • Patients must be at least 18 years of age at study index;
  • Patients must have a diagnosis of PAH. PAH is conventionally defined as a mean pulmonary arterial pressure (PAP) of > 25 mmHg and a pulmonary capillary wedge pressure (PCWP) ≤ 15 mmHg and a pulmonary vascular resistance (PVR) ≥ 240 dynes/s/cm-5 at right heart catheterization;
  • Patients must have initiated sildenafil for the treatment of their PAH; at dose ≥ 20 mg tid within 5 years prior to study initiation

Exclusion Criteria

  • Patient has known contraindications to sildenafil at study index;
  • Patient participated in an investigational study of sildenafil treatment for PAH during the period beginning 6 months prior to study index
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01365585). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search